Clostridium butyricum
Trials 13 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00947336 Comparator | Apr 2005 → Apr 2008 | cirrhosis of liver | Govind Ballabh Pant Hospital | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Clostridium butyricum | “A 10-g packet of lactulose oral solution and three capsules of probiotics (each containing \> 4.2×106 CFU Clostridium butyricum and \> 4.2×105 CFU Bifidobacterium longum infantis).” NCT05687409 ↗13“synbiotic capsules (Streptococcus faecalis JPC 30 million, Clostridium butyricum 2 million, Bacillus mesentericus JPC 1 million, Lactobacillus sporogenes 50 million spores)” NCT00947336 ↗ “This study aimed to assess the efficacy and safety of monotherapy with Clostridium butyricum (C butyricum) and Bacillus coagulans (B coagulans) for H pylori treatment.” PMID 33157939 ↗ Nov 2020 “Clostridium butyricum is a spore-forming bacillus named for its capacity to produce high amounts of butyric acid and is found in soil.” NCT06998823 ↗ “oral probiotics (Clostridium butyricum) work to improve the efficacy” NCT07474064 ↗ “（ clostridium butyricum）” NCT02169388 ↗ |
| Known as | C butyricum | “This study aimed to assess the efficacy and safety of monotherapy with Clostridium butyricum (C butyricum) and Bacillus coagulans (B coagulans) for H pylori treatment.” PMID 33157939 ↗ Nov 2020 |
| Known as | MIYA-BM | “Clostridium butyricum MIYAIRI 588 strain (MIYA-BM) is widely used as probiotic therapy to improve symptoms related to dysbiosis such as constipation, nonantimicrobial diarrhea,...” NCT06998823 ↗ |
| Known as | MIYAIRI 588 strain | “Clostridium butyricum MIYAIRI 588 strain (MIYA-BM) is widely used as probiotic therapy to improve symptoms related to dysbiosis such as constipation, nonantimicrobial diarrhea,...” NCT06998823 ↗ |
| Action | Inhibit | “CONCLUSION: C butyricum and B coagulans may effectively inhibit H pylori to some extent, with rare adverse events, and thus may reduce the burden of antibiotic resistance.” PMID 33157939 ↗ Nov 2020 |
| Modality | Other / unclassified | “Probiotic Clostridium Butyricum” NCT02254629 ↗ |
| Route | Oral | “Participants orally administered the contents three times daily after meals” NCT05687409 ↗ |